The latest parabolic runner on the OTC appears to be Predictive Technology Group Inc (OTCMKTS:PRED). Shares of the stock have been vaulting higher to the tune of 100% upside over the past month as the company’s IP profile continues to improve in the market’s eyes. To add further flesh on the bone, the company just announced that it has completed the integration of two acquired DNA laboratories into the Predictive subsidiary, Predicative Laboratories.
According to the release, “Predictive announced the acquisitions of CLIA-approved Taueret Laboratories in March 2019 and Inception Dx in September 2018. Based in Salt Lake City, Predictive Laboratories runs a state-of-the-art molecular laboratory initially focusing on human infertility and women’s health. Twenty-three skilled employees are performing high-complexity, proprietary laboratory tests. Predictive Laboratories recently purchased $6 million in new genomics equipment and supplies to expand the technical capabilities and capacities. Lab renovation will begin immediately to improve workflow efficiency. The laboratory’s new Federal CLIA number became effective today (46D1077919).”
Predictive Technology Group Inc (OTCMKTS:PRED) promulgates itself as a company that, together with its subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic and pharmaceutical therapeutic/human cells, tissues, and human cellular and tissue-based products (HCT/Ps).
The company operates through two segments, Regenerative Medicine Products and HCT/Ps, and Diagnostics and Therapeutics. It offers ARTguide, a genetic diagnostic and prognostic test for women experiencing infertility as a result of endometriosis and other health concerns; and regenerative medicine products, including AmnioCyteT, AmnioCyte PlusT, PolyCyteT, and CoreCyteT.
The company was formerly known as Global Enterprises Group, Inc. and changed its name to Predictive Technology Group, Inc. in July 2015. Predictive Technology Group, Inc. was founded in 2005 and is headquartered in Salt Lake City, Utah.
According to company materials, “Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively.”
Find out when $PRED reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, PRED just announced that it has completed the integration of two acquired DNA laboratories into the Predictive subsidiary, Predicative Laboratories.
Recent action has seen 61% piled on for shareholders of the stock during the trailing month. Moreover, the company has registered increased average transaction volume recently, with the past month seeing 200% above the average volume levels in play in this stock over the longer term.
“The integration of the Taueret Laboratories team into Predictive Laboratories was completed much faster than anticipated,” said Bradley Robinson, CEO of Predictive Technology Group. “I am excited to have this highly experienced team working to create a leading state-of-the-art laboratory in reproductive health.”
Now commanding a market cap of $1.1B, PRED has a significant war chest ($2.6M) of cash on the books, which is balanced by about $7.3M in total current liabilities. PRED is pulling in trailing 12-month revenues of $30.1M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 233.5%. This is an exciting story, and we look forward to a follow-up chapter as events transpire. Sign-up for continuing coverage on shares of $PRED stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $PRED, either long or short, and we have not been compensated for this article.